Impact of coronary artery calcium on cardiovascular risk categorization and lipid-lowering drug eligibility in asymptomatic hypercholesterolemic men

2011 ◽  
Vol 151 (2) ◽  
pp. 200-204 ◽  
Author(s):  
Gilles Chironi ◽  
Alain Simon ◽  
Jean-Louis Megnien ◽  
Marie-Emmanuelle Sirieix ◽  
Elie Mousseaux ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Coronary Artery ◽  
Coronary Artery Calcium ◽  
Lipid Lowering ◽  
Lipid Lowering Drug ◽  
Lowering Drug ◽  
Risk Categorization

scholarly journals Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study

2018 ◽  
Vol 25 (17) ◽  
pp. 1887-1898 ◽  
Author(s):  
Marcio S Bittencourt ◽  
Ron Blankstein ◽  
Michael J Blaha ◽  
Veit Sandfort ◽  
Arthur S Agatston ◽  
...  
Keyword(s):  
Risk Assessment ◽  
Cardiovascular Risk ◽  
Coronary Artery ◽  
Cardiovascular Mortality ◽  
European Society ◽  
Coronary Artery Calcium ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
European Society Of Cardiology

Aims The European Society of Cardiology (ESC) guideline on cardiovascular risk assessment considers coronary artery calcium a class B indication for risk assessment. We evaluated the degree to which coronary artery calcium can change the recommendation for individuals based on a change in estimated risk. Methods and results We stratified 5602 MESA participants according to the ESC recommendation as: no lipid-lowering treatment recommended ( N = 2228), consider lipid-lowering treatment if uncontrolled ( N = 1686), or lipid-lowering treatment recommended ( N = 1688). We evaluated the ability of coronary artery calcium to reclassify cardiovascular risk. Among the selected sample, 54% had coronary artery calcium of zero, 25% had coronary artery calcium of 1–100 and 21% had coronary artery calcium greater than 100. In the lipid-lowering treatment recommended group 31% had coronary artery calcium of zero, while in the lipid-lowering treatment if uncontrolled group about 50% had coronary artery calcium of zero. The cardiovascular mortality rate was 1.7%/10 years in the lipid-lowering treatment if uncontrolled, and 7.0%/10 years in the lipid-lowering treatment recommended group. The absence of coronary artery calcium was associated with 1.4%/10 years in the lipid-lowering treatment if uncontrolled group and 3.0%/10 years in the lipid-lowering treatment recommended group. Compared with coronary artery calcium of zero, any coronary artery calcium was associated with significantly higher cardiovascular mortality in the lipid-lowering treatment recommended group (9.0%/10 years), whereas only coronary artery calcium greater than 100 was significantly associated with a higher cardiovascular mortality in the lipid-lowering treatment if uncontrolled group (3.2%/10 years). Conclusion The absence of coronary artery calcium is associated with a low incidence of cardiovascular mortality or coronary heart disease events even in individuals in whom lipid-lowering therapy is recommended. A significant proportion of individuals deemed to be candidates for lipid-lowering therapy might be reclassified to a lower risk group with the use of coronary artery calcium.

Berberine: A Promising Natural Isoquinoline Alkaloid for the Development of Hypolipidemic Drugs

2020 ◽  
Vol 20 (28) ◽  
pp. 2634-2647
Author(s):  
Dong-Dong Li ◽  
Pan Yu ◽  
Wei Xiao ◽  
Zhen-Zhong Wang ◽  
Lin-Guo Zhao
Keyword(s):  
Clinical Trials ◽  
Animal Models ◽  
Physicochemical Properties ◽  
Isoquinoline Alkaloid ◽  
Hypolipidemic Activity ◽  
Lipid Lowering ◽  
Lipid Lowering Drug ◽  
Lipid Lowering Agent ◽  
Lowering Drug ◽  
Hypolipidemic Drugs

: Berberine, as a representative isoquinoline alkaloid, exhibits significant hypolipidemic activity in both animal models and clinical trials. Recently, a large number of studies on the lipid-lowering mechanism of berberine and studies for improving its hypolipidemic activity have been reported, but for the most part, they have been either incomplete or not comprehensive. In addition, there have been a few specific reviews on the lipid-reducing effect of berberine. In this paper, the physicochemical properties, the lipid-lowering mechanism, and studies of the modification of berberine all are discussed to promote the development of berberine as a lipid-lowering agent. Subsequently, this paper provides some insights into the deficiencies of berberine in the study of lipid-lowering drug, and based on the situation, some proposals are put forward.

A large remaining potential in lipid‐lowering drug treatment in the type 2 diabetes population – a Danish nationwide cohort study

2021 ◽  
Author(s):  
Hanan Amadid ◽  
Pernille F. Rønn ◽  
Maria BN. Dunbar ◽  
Jakob S. Knudsen ◽  
Bendix Carstensen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Drug Treatment ◽  
Lipid Lowering ◽  
Lipid Lowering Drug ◽  
Lowering Drug

Plasma fibrinogen decrease by a lipid-lowering drug in healthy subjects

1992 ◽  
Vol 65 ◽  
pp. S174
Author(s):  
R. Paniccia ◽  
E. Chiarantini ◽  
M. Boddi ◽  
M. Filippini ◽  
M. Costanzo ◽  
...  
Keyword(s):  
Healthy Subjects ◽  
Plasma Fibrinogen ◽  
Lipid Lowering ◽  
Lipid Lowering Drug ◽  
Lowering Drug
Sign in / Sign up

Export Citation Format

Share Document